Pharmaceutical leaders Lilly and Pfizer are investing in an AI-driven drug discovery startup. These partnerships aim to accelerate the identification of viable therapeutic candidates. While the specific startup remains unnamed in the summary, the move reflects a broader industry trend of integrating machine learning into early-stage R&D to reduce clinical failure rates.